Introduction
Animal welfare mandates adequate analgesia in sepsis models (Lilley E, Shock 2015; 43: 304) . However, it is unclear which regimen is best to achieve this without interfering excessively with the scientific experiments. Nalbuphin, a non-controlled kappa opioid receptor agonist, has a short half live and a wide therapeutic range and might therefore be a useful analgesic for research animals.
Objectives
We test the efficacy and safety of intravenous nalbuphin in our rat model of fecal peritonitis. Here, we report its respiratory and hemodynamic effects in short-term experiments performed in non-septic rats during anaesthesia.
Methods
In this randomized, placebo-controlled, blinded study, spontaneously breathing male Wistar rats were anesthetized with isoflurane 3% (air flow 400 ml/min, FiO2 21%). Nalbuphin (or placebo) was injected subcutaneously at a dose of 1 mg/kg. After local anaesthesia with lidocaine, the left carotid artery and the right jugular vein were surgically cannulated. The isoflurane concentration was reduced to 2%. Intravenous nalbuphin (or placebo) was administered at two different doses (1 and 5 mg/kg/h). Nalbuphin concentration was measured in heparinised plasma by HPLC. Results are given as mean (standard error of the mean), p-values were calculated by a t-test.
Results

See table 1.
Conclusions
Our results demonstrate that high-dose nalbuphin depresses respiratory rate, heart rate and mean arterial pressure in anesthetised rats. In order to investigate if the 1 University Hospital Zurich, Institute of Anesthesiology, Zurich, Switzerland Full list of author information is available at the end of the article Table 1 Results.
Placebo (n=6) Nalbuphin 1 mg/kg/h (n=6) p-value Placebo (n=6) Nalbuphin 5 mg/kg iv (n=6) p-value Nalbuphin concentration [mg/l] 22.9 (3.7)
Respiratory parameters
Respiration rate [1/min] continuous intravenous infusion of nalbuphin influences our long-term sepsis model, further placebo-controlled studies in awake septic and non-septic rats are ongoing.
